Clinical and experimental uses of umbilical cord blood

Lewis, Ian D.

doi:10.1046/j.1445-5994.2002.00276.x

Cited by 29 publications

(15 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The procedures takes about 5 min and poses no risk to mother or baby. Cord blood has emerged as an alternative to bone marrow because of its greater availability, weak immunogenicity, and lower risk of mediating viral transmission (52). Umbilical cord blood banking provides enough number of CD34 + cells needed for a clinical benefit in man.…”

Section: Figmentioning

confidence: 99%

Human Umbilical Cord Blood-Derived Cd34+ Cells Cause Attenuation of Multiorgan Dysfunction During Experimental Heatstroke

Chen¹,

Chang²,

Chang

et al. 2007

Shock

View full text Add to dashboard Cite

Multiorgan dysfunction ensuing from severe heatstroke includes hypotension, hepatic and renal failure, hypercoagulable state, activated inflammation, and cerebral ischemia and injury. We attempted to assess whether human umbilical cord blood-derived CD34+ cell therapy improves survival during experimental heatstroke by attenuating multiorgan dysfunction. Anesthetized rats, immediately after the onset of heatstroke, were divided into 2 major groups and given CD34- or CD34+ cells (1 x 10(5)-5 x 10(5)/mL/kg body weight) i.v. They were exposed to ambient temperature of 43 degrees C to induce heatstroke. Another group of rats were exposed to room temperature (26 degrees C) and used as normothermic controls. Hypotension, hepatic and renal failure (evidenced by increased serum urea nitrogen, creatinine, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels in plasma), hypercoagulable state (evidenced by increased prothrombin time, activated partial thromboplastin time, and D-dimer, and decreased platelet count and protein C in plasma), activated inflammation (evidence by increased TNF-alpha levels in serum), and cerebral dysfunction (evidenced by intracranial hypertension, cerebral hypoperfusion and hypoxia, and cerebral ischemia and injury) were monitored. When the CD34- cell-treated or untreated rats underwent heat stress, their survival time values were found to be 19 to 23 min. Resuscitation with CD34+ cells significantly improved survival time (duration, 63-291 min). As compared with normothermic controls, all CD34- cell-treated heatstroke animals displayed hypotension, hepatic and renal failure, hypercoagulable state, activated inflammation, and cerebral ischemia and injury. However, CD34+ cell therapy significantly caused attenuation of all the above-mentioned heatstroke reactions. In addition, the levels of IL-10 in plasma and glial cell line-derived neurotrophic factors in brain were all significantly increased after CD34+ cell therapy during heatstroke. Our data indicate that CD34+ cell therapy may resuscitate persons who had a heatstroke by reducing multiorgan dysfunction or failure.

show abstract

Section: Figmentioning

confidence: 99%

Human Umbilical Cord Blood-Derived Cd34+ Cells Cause Attenuation of Multiorgan Dysfunction During Experimental Heatstroke

Chen¹,

Chang²,

Chang

et al. 2007

Shock

View full text Add to dashboard Cite

show abstract

“…6 -9 Cord blood has emerged as an alternative to bone marrow because of its greater availability, weak immunogenicity, and lower risk of mediating viral transmission. 10 We have reported significant behavioral benefit after intravenous infusion of human umbilical cord blood cells (HUCBC) in the rat middle cerebral artery occlusion (MCAO) model of stroke. 8,11 Moreover, we demonstrated that intravenous infused HUCBC was comparable to, if not better than, intrastriatally transplanted HUCBC in mediating behavioral recovery after MCAO.…”

mentioning

confidence: 99%

Infusion of Human Umbilical Cord Blood Cells in a Rat Model of Stroke Dose-Dependently Rescues Behavioral Deficits and Reduces Infarct Volume

Vendrame

Cassady

Newcomb

et al. 2004

Stroke

351

296

View full text Add to dashboard Cite

Background and Purpose-Intravenously delivered human umbilical cord blood cells (HUCBC) have been previouslyshown to improve functional recovery of stroked rats. To extend these findings, we examined the behavioral recovery and stroke infarct volume in the presence of increasing doses of HUCBC after permanent middle cerebral artery occlusion (MCAO). Methods-Rats were subjected to MCAO and allowed to recover for 24 hours before intravenous infusion of 10 4 up to 3 to 5ϫ10 7 HUCBC. Behavioral tests (spontaneous activity, step test, elevated body swing test) were performed 1 week before MCAO and at 2 and 4 weeks after HUCBC infusion. On completion of behavioral testing, animals were euthanized and brain infarct volumes quantified. HUCBC were identified by immunofluorescence for human nuclei and by polymerase chain reaction (PCR) using primers specific for human glycerol 3-phosphate dehydrogenase. Results-At 4 weeks after infusion, there was a significant recovery in behavioral performance when 10 6 or more HUCBC were delivered (pϭ0.001 to pϭ0.05). Infarct volume measurements revealed an inverse relationship between HUCBC dose and damage volume, which reached significance at the higher HUCBC doses (10 7 cells, pϽ0.01; 3 to 5ϫ10 7 cells, pϽ0.05). Moreover, HUCBC were localized by immunohistochemistry and PCR analysis only in the injured brain hemisphere and spleen. Conclusions-These results extend previous observations of HUCBC infusion in the MCAO rat stroke model by demonstrating a dose relationship between HUCBC, behavioral improvement, and neuronal sparing.

show abstract

“…More recently, peripheral blood (after treatment of the donor with cytokines to mobilize stem cells) has been found to be a better source of stem cells to restore hematopoiesis (85). Umbilical cord blood (UCB) can also be used and has several advantages over bone marrow as a source of HSCs, especially in pediatric patients (86). In principle, the HSCs are the only cells required to restore the ablated hematopoietic system.…”

Section: Stem Cell Therapiesmentioning

confidence: 99%

Mammalian Stem Cells

2006

View full text Add to dashboard Cite

Stem cells are quickly coming into focus of much biomedical research eventually aiming at the therapeutic applications for various disorders and trauma. It is important, however, to keep in mind the difference between the embryonic stem cells, somatic stem cells and somatic precursor cells when considering potential clinical applications. Here we provide the review of the current status of stem cell field and discuss the potential of therapeutic applications for blood and Immune system disorders, multiple sclerosis, hypoxicischemic brain injury and brain tumors. For the complimentary information about various stem cells and their properties we recommend consulting the National Institutes of Health stem cell resources

show abstract

Clinical and experimental uses of umbilical cord blood

Cited by 29 publications

References 50 publications

Human Umbilical Cord Blood-Derived Cd34+ Cells Cause Attenuation of Multiorgan Dysfunction During Experimental Heatstroke

Human Umbilical Cord Blood-Derived Cd34+ Cells Cause Attenuation of Multiorgan Dysfunction During Experimental Heatstroke

Infusion of Human Umbilical Cord Blood Cells in a Rat Model of Stroke Dose-Dependently Rescues Behavioral Deficits and Reduces Infarct Volume

Mammalian Stem Cells

Contact Info

Product

Resources

About